DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
NCT ID : N/A
Protocol Number : CBI_2019_SLNBprosp_001
Phase : N/A
Location : Santa Monica, CA
|
Richard Essner, M.D.
|
A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment
NCT ID : 03978611
Protocol Number : CA224-083
Phase : 1/2
Location : Santa Monica, CA
|
Timothy Kristedja, M.D.
|
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
NCT ID : 04526899
Protocol Number : BNT111-01
Phase : 2
Location : Santa Monica, CA
|
Przemyslaw Twardowski, M.D.
|
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
NCT ID : 04410445
Protocol Number : 20-214-29/CA045-022
Phase : 3
Location : Santa Monica, CA
|
Steven O' Day, M.D.
|
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)
NCT ID : 04303169
Protocol Number : MK-3475-02C
Phase : 3
Location : Santa Monica, CA
|
Timothy Kristedja, M.D.
|
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)
NCT ID : 04305054
Protocol Number : MK-3475-02B
Phase : 3
Location : Santa Monica, CA
|
Przemyslaw Twardowski, M.D.
|
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT ID : 04382664
Protocol Number : UV1-202
Phase : 2
Location : Santa Monica, CA
|
Przemyslaw Twardowski, M.D.
|
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
NCT ID : 03978611
Protocol Number : CA224-083
Phase : 1/2a
Location : Santa Monica, CA
|
Steven O' Day, M.D.
|
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
|
Steven O' Day, M.D.
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : 3
Location : Santa Monica, CA
|
Steven O' Day, M.D.
|